RSSDI is the largest association of diabetologist in Asia with over 13,000 members.
KCDD - RSSDI aims to develop a competitive marketplace in India for advanced diabetes devices including Continuous Glucose Monitors (CGMs), Insulin Pumps, and Automated Insulin Delivery Systems to reduce costs and improve access for patients.
Continuous Glucose Monitoring (CGM) is among the most impactful medical technologies in diabetes care. By providing real time glucose data, CGMs enable better glycemic control, particularly in high-risk groups and empower patients with self-management tools to regulate insulin in real time.
With over 100 million people living with diabetes in India (projected to reach 125 million by 2030), the need for innovative management tools is growing rapidly. However, CGM adoption remains low due to high device costs and limited clinician awareness and training.
By addressing both supply and demand-side barriers, KCDD - RSSDI is working on unlocking the full potential of CGMs and other diabetes technologies aimed at expanding access, lowering costs, and improving long-term health outcomes nationwide.
Developing CGM technology requires deep expertise in chemistry, biology, biomedical engineering, and regulatory sciences. Progress will need coordinated action across startups, academia, industry, and government.
By connecting global leaders, supporting Indian innovators, and building awareness among clinicians and patients, KCDD - RSSDI aims to accelerate CGM adoption in India. This will not only strengthen diabetes care but also empower millions of patients with real-time, data-driven tools for better health outcomes.
